Apellis Pharmaceuticals
Yahoo Finance • 5 months ago
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
Apellis Pharmaceuticals, Inc. WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (... Full story
Yahoo Finance • 6 months ago
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Apellis Pharmaceuticals, Inc. Rapid reduction in disease activity seen at 12 weeks was sustained at one year 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared Highlighted as late-breaking oral... Full story
Yahoo Finance • 8 months ago
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story
Yahoo Finance • 11 months ago
Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks
In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. In t... Full story
Yahoo Finance • last year
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023... Full story
Yahoo Finance • last year
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to 20 new employees with a grant date of November 1, 2023, as equity indu... Full story
Yahoo Finance • last year
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension study Well-demonstrated safety profile consistent with previously reported clinical data Approximately 92% of pa... Full story
Yahoo Finance • last year
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) on behalf of long-term s... Full story
Yahoo Finance • last year
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for EMPAVELI® (pegcetacoplan) SYFOVRE showed continued strong demand with growth week-over-we... Full story
Yahoo Finance • last year
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, Nov... Full story
Yahoo Finance • last year
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
SYFOVRE demonstrated clinically meaningful reductions in GA lesion growth in as few as six doses per year Only treatment approved for use beyond 12 months for GA, a chronic disease and leading cause of vision loss WALTHAM, Mass., Oct. 20... Full story
Yahoo Finance • last year
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
In as early as 12 weeks: 80% of patients treated with pegcetacoplan showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline40% of patients showed zero staining intensity, indicating that C3c deposi... Full story
Yahoo Finance • last year
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
Continued strong demand, with more than 100,000 vials (commercial and sample) distributed to date; growth in week-over-week demand returned starting in August Permanent J-code effective as of October 1, and more than 95% of all Medicare pa... Full story
Yahoo Finance • last year
DEADLINE ALERT for EOSE, APLS, and HAYW: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story
Yahoo Finance • last year
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
Compact, single-use, on-body injector designed to enhance the patient experience of administering EMPAVELI® (pegcetacoplan) WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced t... Full story
Yahoo Finance • last year
Lifshitz Law PLLC Announces Investigations of Apellis Pharmaceutics, Inc. (NASDAQ: APLS), RTX Corp. (NYSE: RTX), Live Nation Entertainment, Inc. (NYSE: LYV), and KeyCorp (NYSE: KEY)
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegat... Full story
Yahoo Finance • last year
APLS 截止日期提醒：業內領先的律所 ROSEN 鼓勵損失超過 10 萬美元的 Apellis Pharmaceuticals, Inc. 投資者在證券集體訴訟的重要截止日期 10 月 2 日前聘請律師 – APLS
紐約, Oct. 01, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒於 2021 年 1 月 28 日至 2023 年 7 月 28 日（含上述兩日）期間（簡稱「集體訴訟期」）購買 Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) 普通股之人士注意，重要的首席原告截止日期是 2023 年 10 月 2 日。 影響：若您曾在集體訴訟期內購買了 Apellis... Full story
Yahoo Finance • last year
APLS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action – APLS
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dat... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Apellis Pharmaceuticals, Inc. (APLS) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks... Full story
Yahoo Finance • last year
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Apellis Investors of a Lead Plaintiff Deadline of October 2, 2023
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Attention Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ: APLS) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who... Full story
